{"transactions":[{"id":2055968,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Debt convertible into Common Stock","published_at":"2023-01-13T02:21:20.000Z","date":"2023-01-10","kind":"purchase","acquired":true,"price":30000000,"reported_value":30000000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"security","element":"securityTitle","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"security","element":"securityTitle","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"security","element":"securityTitle","label":"F5","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. In 2021, Innoviva designated Jules Haimovitz, a member of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. In 2021, Innoviva designated Jules Haimovitz, a member of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4."}],"derivative":{"exercise_price":1.52,"underlying":"Common Stock","underlying_shares":19736843},"source":{"system":"sec-edgar","filing":"0001104659-23-003540","document":"tm232524-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923003540/tm232524-2_4seq1.xml","form_type":"4"}},{"id":2208210,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"ten_percent_owner":true}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2022-07-14T01:27:34.000Z","date":"2022-07-11","kind":"purchase","acquired":true,"shares":7598814,"price":2.2,"value":16717390.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the shares and warrants were cancelled on July 11, 2022 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of May 23, 2022 (the \"Merger Agreement\"), by and among Innoviva, Inc. (\"Innoviva\"), Innoviva Merger Sub, Inc., a wholly owned subsidiary of Innoviva (\"Merger Sub\"), and Entasis Therapeutics Holdings Inc. (\"Entasis\"). Following effectiveness of the merger provided for in the Merger Agreement, Innoviva owns 100 shares of the common stock of Entasis, which became a wholly owned subsidiary of Innoviva as a result of such merger, which represents all of the outstanding shares of common stock of Entasis. Innoviva will not issue itself replacement warrants."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All of the shares and warrants were cancelled on July 11, 2022 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of May 23, 2022 (the \"Merger Agreement\"), by and among Innoviva, Inc. (\"Innoviva\"), Innoviva Merger Sub, Inc., a wholly owned subsidiary of Innoviva (\"Merger Sub\"), and Entasis Therapeutics Holdings Inc. (\"Entasis\"). Following effectiveness of the merger provided for in the Merger Agreement, Innoviva owns 100 shares of the common stock of Entasis, which became a wholly owned subsidiary of Innoviva as a result of such merger, which represents all of the outstanding shares of common stock of Entasis. Innoviva will not issue itself replacement warrants."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and Innoviva, pursuant to the Merger Agreement, for any and all outstanding shares of Entasis common stock pursuant to that certain Offer to Purchase, dated June 7, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Shares acquired pursuant to the merger provided for in the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva (\"ISO\") with the U.S. Securities and Exchange Commission (the \"SEC\") on May 3, 2021, in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement (the \"Securities Purchase Agreement\"), dated as of May 3, 2021, by and between Entasis and ISO, ISO acquired 3,731,025 shares of common stock of Entasis and warrants to purchase an additional 3,731,025 shares for an aggregate price of $2.00 per share and warrant. As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva and ISO with the SEC on June 11, 2021, in connection the closing that occurred on June 11, 2021 pursuant to the Securities Purchase Agreement, ISO acquired 6,268,975 shares of common stock of Entasis and warrants to purchase an additional 6,268,975 shares for an aggregate price of $2.00 per share and warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and Innoviva, pursuant to the Merger Agreement, for any and all outstanding shares of Entasis common stock pursuant to that certain Offer to Purchase, dated June 7, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares acquired pursuant to the merger provided for in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva (\"ISO\") with the U.S. Securities and Exchange Commission (the \"SEC\") on May 3, 2021, in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement (the \"Securities Purchase Agreement\"), dated as of May 3, 2021, by and between Entasis and ISO, ISO acquired 3,731,025 shares of common stock of Entasis and warrants to purchase an additional 3,731,025 shares for an aggregate price of $2.00 per share and warrant. As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva and ISO with the SEC on June 11, 2021, in connection the closing that occurred on June 11, 2021 pursuant to the Securities Purchase Agreement, ISO acquired 6,268,975 shares of common stock of Entasis and warrants to purchase an additional 6,268,975 shares for an aggregate price of $2.00 per share and warrant."}],"balance_after":29270476,"source":{"system":"sec-edgar","filing":"0001140361-22-025957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000114036122025957/form4.xml","form_type":"4"}},{"id":2208209,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"ten_percent_owner":true}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2022-07-14T01:27:34.000Z","date":"2022-07-08","kind":"purchase","acquired":true,"shares":11671662,"price":2.2,"value":25677656.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the shares and warrants were cancelled on July 11, 2022 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of May 23, 2022 (the \"Merger Agreement\"), by and among Innoviva, Inc. (\"Innoviva\"), Innoviva Merger Sub, Inc., a wholly owned subsidiary of Innoviva (\"Merger Sub\"), and Entasis Therapeutics Holdings Inc. (\"Entasis\"). Following effectiveness of the merger provided for in the Merger Agreement, Innoviva owns 100 shares of the common stock of Entasis, which became a wholly owned subsidiary of Innoviva as a result of such merger, which represents all of the outstanding shares of common stock of Entasis. Innoviva will not issue itself replacement warrants."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All of the shares and warrants were cancelled on July 11, 2022 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of May 23, 2022 (the \"Merger Agreement\"), by and among Innoviva, Inc. (\"Innoviva\"), Innoviva Merger Sub, Inc., a wholly owned subsidiary of Innoviva (\"Merger Sub\"), and Entasis Therapeutics Holdings Inc. (\"Entasis\"). Following effectiveness of the merger provided for in the Merger Agreement, Innoviva owns 100 shares of the common stock of Entasis, which became a wholly owned subsidiary of Innoviva as a result of such merger, which represents all of the outstanding shares of common stock of Entasis. Innoviva will not issue itself replacement warrants."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and Innoviva, pursuant to the Merger Agreement, for any and all outstanding shares of Entasis common stock pursuant to that certain Offer to Purchase, dated June 7, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva (\"ISO\") with the U.S. Securities and Exchange Commission (the \"SEC\") on May 3, 2021, in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement (the \"Securities Purchase Agreement\"), dated as of May 3, 2021, by and between Entasis and ISO, ISO acquired 3,731,025 shares of common stock of Entasis and warrants to purchase an additional 3,731,025 shares for an aggregate price of $2.00 per share and warrant. As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva and ISO with the SEC on June 11, 2021, in connection the closing that occurred on June 11, 2021 pursuant to the Securities Purchase Agreement, ISO acquired 6,268,975 shares of common stock of Entasis and warrants to purchase an additional 6,268,975 shares for an aggregate price of $2.00 per share and warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and Innoviva, pursuant to the Merger Agreement, for any and all outstanding shares of Entasis common stock pursuant to that certain Offer to Purchase, dated June 7, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva (\"ISO\") with the U.S. Securities and Exchange Commission (the \"SEC\") on May 3, 2021, in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement (the \"Securities Purchase Agreement\"), dated as of May 3, 2021, by and between Entasis and ISO, ISO acquired 3,731,025 shares of common stock of Entasis and warrants to purchase an additional 3,731,025 shares for an aggregate price of $2.00 per share and warrant. As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva and ISO with the SEC on June 11, 2021, in connection the closing that occurred on June 11, 2021 pursuant to the Securities Purchase Agreement, ISO acquired 6,268,975 shares of common stock of Entasis and warrants to purchase an additional 6,268,975 shares for an aggregate price of $2.00 per share and warrant."}],"balance_after":21671662,"source":{"system":"sec-edgar","filing":"0001140361-22-025957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000114036122025957/form4.xml","form_type":"4"}},{"id":2311824,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-04-01T20:52:45.000Z","date":"2022-03-31","kind":"purchase","acquired":true,"shares":0,"price":5,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Exhibit 99.1"},{"field":"security","element":"securityTitle","label":"F2","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":2692604,"derivative":{"exercise_price":5,"exercise_date":"2022-03-31","expiration_date":"2027-03-31","underlying":"Common Stock","underlying_shares":2692604},"source":{"system":"sec-edgar","filing":"0001567619-22-007861","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922007861/doc1.xml","form_type":"4"}},{"id":2311823,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T20:52:45.000Z","date":"2022-03-31","kind":"purchase","acquired":true,"shares":5385208,"price":5,"value":26926040.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":16365969,"source":{"system":"sec-edgar","filing":"0001567619-22-007861","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922007861/doc1.xml","form_type":"4"}},{"id":2379758,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-02-23T18:05:12.000Z","date":"2022-02-18","kind":"other","acquired":true,"shares":0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"See Exhibit 99.1"},{"field":"shares","element":"transactionShares","label":"F3","text":"See Exhibit 99.1"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"See Exhibit 99.1"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"See Exhibit 99.1"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"See Exhibit 99.1"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"See Exhibit 99.1"}],"balance_after":10000000,"derivative":{"exercise_price":1.48,"expiration_date":"2022-08-18","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001567619-22-005338","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761922005338/doc1.xml","form_type":"4"}},{"id":2379757,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2022-02-23T18:05:12.000Z","date":"2022-02-18","kind":"other","acquired":true,"shares":0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"See Exhibit 99.1"},{"field":"shares","element":"transactionShares","label":"F3","text":"See Exhibit 99.1"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"See Exhibit 99.1"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"See Exhibit 99.1"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"See Exhibit 99.1"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"See Exhibit 99.1"}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2022-08-18","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001567619-22-005338","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761922005338/doc1.xml","form_type":"4"}},{"id":2402608,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-02-11T23:56:05.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":1807396,"price":5,"value":9036980.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Exhibit 99.1"},{"field":"security","element":"securityTitle","label":"F2","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":1807396,"derivative":{"exercise_price":5,"exercise_date":"2022-02-09","expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":1807396},"source":{"system":"sec-edgar","filing":"0001567619-22-003750","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922003750/doc1.xml","form_type":"4"}},{"id":2402607,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-11T23:56:05.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":3614792,"price":5,"value":18073960.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":10980761,"source":{"system":"sec-edgar","filing":"0001567619-22-003750","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922003750/doc1.xml","form_type":"4"}},{"id":2531093,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-01T18:20:02.000Z","date":"2021-10-29","kind":"purchase","acquired":true,"shares":1212122,"price":3.3,"value":4000002.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 28, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and another purchaser, pursuant to which, on October 29, 2021 Innoviva Sub acquired 1,212,122 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\").  In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of an additional 6,153,847 shares of Common Stock and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and in 2021, Innoviva designated Jules Haimovitz, two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4."}],"balance_after":7365969,"source":{"system":"sec-edgar","filing":"0001567619-21-019063","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761921019063/doc1.xml","form_type":"4"}},{"id":2672546,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2021-06-11T21:39:43.000Z","date":"2021-06-11","kind":"purchase","acquired":true,"shares":6268975,"price":2,"value":12537950.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on June 11, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 6,268,975 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on June 11, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 6,268,975 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021."}],"balance_after":10000000,"derivative":{"exercise_price":2,"exercise_date":"2021-06-11","expiration_date":"2026-06-11","underlying":"Common Stock","underlying_shares":6268975},"source":{"system":"sec-edgar","filing":"0001567619-21-012030","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761921012030/doc1.xml","form_type":"4"}},{"id":2672545,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-11T21:39:43.000Z","date":"2021-06-11","kind":"purchase","acquired":true,"shares":6268975,"price":2,"value":12537950.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on June 11, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 6,268,975 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on June 11, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 6,268,975 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021."}],"balance_after":10000000,"source":{"system":"sec-edgar","filing":"0001567619-21-012030","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761921012030/doc1.xml","form_type":"4"}},{"id":2703786,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2021-05-20T18:39:41.000Z","date":"2021-05-03","kind":"purchase","acquired":true,"shares":3731025,"price":2,"value":7462050.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on May 3, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 3,731,025 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on May 3, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 3,731,025 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4."}],"balance_after":3731025,"derivative":{"exercise_price":2,"exercise_date":"2021-05-03","expiration_date":"2026-05-03","underlying":"Common Stock","underlying_shares":3731025},"source":{"system":"sec-edgar","filing":"0001567619-21-010772","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761921010772/doc1.xml","form_type":"4"}},{"id":2703785,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-20T18:39:41.000Z","date":"2021-05-03","kind":"purchase","acquired":true,"shares":3731025,"price":2,"value":7462050.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. (\"INVA\") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA (\"ISO\" and together with INVA, the \"Reporting Persons\") with the U.S. Securities and Exchange Commission on May 3, 2021 (the \"Schedule 13D/A\"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the \"Purchase Agreement\" and, such closing, the \"Closing\"), by and between Entasis Therapeutics Holdings Inc. (the \"Issuer\") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer (\"Shares\") and warrants to purchase an additional 3,731,025 Shares (\"Warrants\" and together with the Shares, the \"Security\") for an aggregate price of $2.00 per Security as set forth in this Form 4."}],"balance_after":3731025,"source":{"system":"sec-edgar","filing":"0001567619-21-010772","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761921010772/doc1.xml","form_type":"4"}},{"id":2783982,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2021-03-17T21:16:08.000Z","date":"2021-03-17","kind":"purchase","acquired":true,"shares":4285935,"price":3.25,"value":13929288.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Ex. 99.1."},{"field":"security","element":"securityTitle","label":"F2","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Ex. 99.1."}],"balance_after":6153847,"derivative":{"exercise_price":3.25,"exercise_date":"2021-03-17","expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":4285935},"source":{"system":"sec-edgar","filing":"0001567619-21-006518","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761921006518/doc1.xml","form_type":"4"}},{"id":2783981,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-17T21:16:08.000Z","date":"2021-03-17","kind":"purchase","acquired":true,"shares":4285935,"price":3.25,"value":13929288.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Ex. 99.1."},{"field":"security","element":"securityTitle","label":"F2","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Ex. 99.1."}],"balance_after":6153847,"source":{"system":"sec-edgar","filing":"0001567619-21-006518","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761921006518/doc1.xml","form_type":"4"}},{"id":2892591,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2021-01-28T18:43:45.000Z","date":"2021-01-26","kind":"purchase","acquired":true,"shares":1867912,"price":3.25,"value":6070714.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"security","element":"securityTitle","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."}],"balance_after":1867912,"derivative":{"exercise_price":3.25,"exercise_date":"2021-01-26","expiration_date":"2026-01-26","underlying":"Common Stock","underlying_shares":1867912},"source":{"system":"sec-edgar","filing":"0000899243-21-003595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000089924321003595/doc4.xml","form_type":"4"}},{"id":2892590,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-28T18:43:45.000Z","date":"2021-01-26","kind":"purchase","acquired":true,"shares":1867912,"price":3.25,"value":6070714.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"security","element":"securityTitle","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."}],"balance_after":1867912,"source":{"system":"sec-edgar","filing":"0000899243-21-003595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000089924321003595/doc4.xml","form_type":"4"}}]}